R 0007/15 (Petition for review admissible but not allowable) of 15.05.2017
- European Case Law Identifier
- ECLI:EP:BA:2017:R000715.20170515
- Date of decision
- 15 May 2017
- Case number
- R 0007/15
- Online on
- 23 October 2017
- Petition for review of
- T 1651/11 (Apremilast against psoriasis/CELGENE) of 17.03.2015
- Application number
- 03721414.5
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen and members (B)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE FOR USE IN TREATING PSORIASIS BY ORAL ADMINISTRATION
- Applicant name
- CELGENE CORPORATION
- Opponent name
- Ratiopharm GmbH
- Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 112a(2)(c)European Patent Convention Art 113European Patent Convention Art 123(2)European Patent Convention R 106
- Keywords
- Violation of the right to be heard, no
- Catchword
- -
- Cited cases
- R 0001/08R 0007/09R 0012/09R 0015/09R 0015/10R 0022/10R 0006/11R 0015/11R 0015/12R 0015/13J 0003/90
- Citing cases
- R 0002/25
Order
For these reasons it is decided that:
The petition for review is rejected as being unallowable.